Top brand choice
Strength | Pack Size | Qty | |
---|---|---|---|
Strength
100mg
|
|||
Strength
500mg
|
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Bosulif, or Bosutinib, is a tyrosine kinase inhibitor for treating adult patients with chronic, accelerated, or blast-phase Philadelphia-chromosome-positive chronic myelogenous leukemia (CML).
It works by interfering with the abnormal signals responsible for the growth of cancer cells. This medication is often part of a comprehensive treatment plan for patients with certain forms of leukemia.
Fact Table | |
---|---|
Formula | C26H29Cl2N5O3 |
License | FDA approved |
Bioavailability | Approximately 34% |
Legal status | Prescription only |
Chemical Name | 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile monohydrate |
Elimination half-life | Approximately 22-24 hours |
Dosage (Strength) | 100 mg, 400 mg, 500 mg tablets |
Pregnancy | Not recommended; consult a healthcare provider |
Brands | Bosulif |
Protein binding | >95% |
PubChem CID | 5328940 |
MedlinePlus | a613043 |
ChEBI | 78543 |
ATC code | L01EA04 |
DrugBank | DB06616 |
KEGG | D09935 |
Routes of administration | Oral |
The starting dosage is 500 mg once daily and can be adjusted to 200-600 mg daily based on patient factors.
The active ingredient in Bosulif is bosutinib.
Common drug-drug interactions may include:
Tell your doctor if you have a history of chronic infection, gastrointestinal problems, fluid retention, or liver problems.
Do not take this drug if you are pregnant or planning to become pregnant.
The most common side effects of this drug include:
Bosulif [package insert]. New York, NY: Pfizer; September 2012.